ProPhase Labs (PRPH) Upgraded to “C-” by TheStreet
ProPhase Labs stock opened at $2.99 on Wednesday. ProPhase Labs has a 1 year low of $2.03 and a 1 year high of $6.64. The company has a market capitalization of $34.28 million, a P/E ratio of 3.86 and a beta of 0.09.
ProPhase Labs (NASDAQ:PRPH) last released its earnings results on Monday, August 20th. The company reported ($0.02) earnings per share (EPS) for the quarter. ProPhase Labs had a negative net margin of 8.88% and a negative return on equity of 3.81%. The company had revenue of $3.19 million during the quarter.
ProPhase Labs Company Profile
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.